<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04584086</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A02023-36</org_study_id>
    <nct_id>NCT04584086</nct_id>
  </id_info>
  <brief_title>Changes in the MRI Signal in Patients With Benign Tumors of the Brain and Meninges Treated With Proton Therapy: Impact of TEL and the Biological Dose Received</brief_title>
  <acronym>BRAIN TEL</acronym>
  <official_title>Changes in the MRI Signal in Patients With Benign Tumors of the Brain and Meninges Treated With Proton Therapy: Impact of TEL and the Biological Dose Received</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to detect with TESLA multiparametric 3 MRI, the MRI secondary changes&#xD;
      to protontherapy irradiation and to correlate them with TEL mapping, physical dose and&#xD;
      biological dose. A model should thus be able to be proposed at the end of the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate by TESLA multiparametric 3 MRI the modifications of the MRI signal :Change from Baseline at 1, 3 and 6 months</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>modifications of the MRI signal on the various sequences carried out, during the study</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Benign Brain Tumors</condition>
  <condition>Proton Therapy</condition>
  <arm_group>
    <arm_group_label>MRI 3 Tesla</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be followed by 3 Tesla MRIs during the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI 3 tesla</intervention_name>
    <description>1.5 Tesla MRIs, usually used as pre-treatment and, between 3 and 6 months after irradiation, are replaced in the study by 3 Tesla MRIs (pre-treatment and at 6 months)&#xD;
In addition, two additional MRIs, also performed with a 3 Tesla magnetic field, will be performed:&#xD;
During treatment when half of the prescribed dose has been delivered.&#xD;
1 month after the end of the irradiation.</description>
    <arm_group_label>MRI 3 Tesla</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven or highly probable grade I meningiomas, histologically proven&#xD;
             grade II meningiomas.&#xD;
&#xD;
          -  Only meningiomas of the anterior and middle floors of the base of the skull are&#xD;
             included.&#xD;
&#xD;
          -  Indication of proton therapy retained in RCP and / or proton therapy technical staff&#xD;
             (Caen site)&#xD;
&#xD;
          -  Patient aged 18 or over&#xD;
&#xD;
          -  Patient affiliated to a social security scheme&#xD;
&#xD;
          -  Signature of informed consent before any specific procedure related to the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of brain or face irradiation.&#xD;
&#xD;
          -  Implant or foreign body that can alter MRI imaging.&#xD;
&#xD;
          -  Contraindication to MRI (pace maker, claustrophobia ...) - Hypersensitivity to&#xD;
             gadoteric acid, to meglumine or to any medicine containing gadolinium&#xD;
&#xD;
          -  Genetic radio sensitizing syndrome&#xD;
&#xD;
          -  Known neurological comorbidities (stroke, Parkinson's, etc.) that may impact MRI data.&#xD;
&#xD;
          -  Simultaneous participation in a therapeutic clinical trial&#xD;
&#xD;
          -  Patient unable to undergo the trial follow-up for geographic, social or&#xD;
             psychopathological reasons&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Persons deprived of their liberty (see article L 1121-6 CSP),&#xD;
&#xD;
          -  Adults who are the subject of a legal protection measure or unable to express their&#xD;
             consent (see article L 1121-8)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paul LESUEUR, MD</last_name>
    <phone>0231455020</phone>
    <email>p.lesueur@baclesse.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Fran√ßois Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul LESUEUR, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 1, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2020</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

